Takeda and London School of Hygiene & Tropical Medicine Establish "Takeda Chair in Global Child Health"
16.5.2019 09:00:00 EEST | Business Wire | Press release
Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) and the London School of Hygiene & Tropical Medicine (LSHTM) will announce today at the evening reception, hosted by the Embassy of Japan in the United Kingdom, the establishment of the Takeda Chair in Global Child Health, endowed by a £3 million donation by Takeda to LSHTM. The School’s first fully endowed corporate chair, it will support vital research into reducing 5.3 million child deaths in low and middle-income countries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190515006091/en/
Takeda’s donation will enable LSHTM to recruit a world-class researcher and educator to join its innovative academic team as the first holder of the Takeda Chair in Global Child Health. This post will play a critical role in consolidating LSHTM’s child health research across more than 100 countries, accelerating change for one of the biggest global health challenges, and further strengthening LSHTM’s position as a leader in maternal, child and adolescent health.
Christophe Weber, President and CEO of Takeda, stated, “Takeda’s aim is to thrive at the cutting edge of innovation that helps solve unmet medical needs, both through our own R&D and in collaboration with exceptional partners across the globe. We believe that global health research and the training of new global healthcare professionals are essential to the ongoing translation of science into life-changing therapies for patients. This Chair does both. We are excited to partner with LSHTM, renowned for its pioneering research and uniquely placed to realize the full potential impact of the Chair, and in doing so directly benefitting millions of children and their families.”
Through its Corporate Social Responsibility (CSR) activities, Takeda has supported health worker training and capacity building, immunization campaigns, health system strengthening and maternal, child and newborn health in the developing world for over a decade. Additionally, Takeda has a long history of supporting child health beyond CSR. For over 70 years, the company has supplied critical vaccines to the children of Japan, and more recently is working to expand impact on global health beyond Japan through a pipeline with the potential to transform the global picture for several neglected diseases.
More than five million children under the age of five die each year, half of whom die within the neonatal period (birth to one month old), with the next largest number being due to childhood infections such as pneumonia and diarrhea. While the vast majority of these deaths are preventable, key research gaps remain. The Takeda Chair in Global Child Health will enable a ‘rising star’ to bridge research, public policy, and healthcare delivery by developing thought leadership in child survival and health through innovative research, including vaccines, neonatal care, under-nutrition, and infection diagnostics and treatments.
Professor Baron Peter Piot, Director of LSHTM, stated, “We are honored to partner with Takeda to create this Professorial Chair, the first in our School’s history to have been fully endowed through corporate support. This donation is incredibly valuable, providing ongoing funding and support for a Professorial Chair in Global Child Health – a pivotal part of our continuing mission to improve health worldwide. We are deeply thankful to Takeda for their generosity as we work together to transform the health of future generations.”
Professor Joy Lawn, Director of LSHTM’s MARCH Centre (Maternal Adolescent, Reproductive & Child Health Centre), said, “The Takeda Chair will advance the evidence base for child survival and child health around the world, enable innovations and drive an important emphasis on the science and realities of healthcare implementation. This Chair will be instrumental in linking evidence to action, especially in sub-Saharan Africa and South Asia, where the majority of child deaths occur. We are grateful for Takeda’s generous support which will advance child health worldwide, and aligns with the mission of the London School of Hygiene & Tropical Medicine and our school’s MARCH Centre.”
International recruitment for the Takeda Chair in Global Child Health will begin in May. Due to the perpetual nature of this endowment, this role will be awarded to generations of academics, enabling the best and brightest academic minds to have the freedom to explore innovative ways to improve global health.
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Rare Diseases and Neuroscience. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
For more information, visit https://www.takeda.com
About the London School of Hygiene & Tropical Medicine
The London School of Hygiene & Tropical Medicine is a world-leading centre for research and postgraduate education in public and global health, with 4,500 students and more than 3,000 staff working in over 100 countries. LSHTM is one of the highest-rated research institutions in the UK, and among the world's leading schools in public and global health. Our mission is to improve health and health equity in the UK and worldwide; working in partnership to achieve excellence in public and global health research, education and translation of knowledge into policy and practice. For more information, visit www.lshtm.ac.uk and https://march.lshtm.ac.uk/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190515006091/en/
Contact information
Media Inquiries:
The Press Office at LSHTM
press@lshtm.ac.uk
+44(0)207
927 2802
Takeda Pharmaceutical Company
Kazumi Kobayashi
kazumi.kobayashi@takeda.com
+81
3 3278 2095
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NetJets Becomes Official Private Aviation Provider of the Hahnenkamm Races in Kitzbühel20.11.2026 19:45:00 EET | Press release
NetJets, the global leader in private aviation, is delighted to announce its newest partnership with the Hahnenkamm Races in Kitzbühel, Austria, becoming the event's Official Private Aviation Provider. The Hahnenkamm Races are among the most prestigious and celebrated events in world alpine skiing. They attract athletes, business leaders, international guests and winter sports enthusiasts from around the world. Through this partnership, NetJets and the Hahnenkamm Races are aligning two brands renowned for excellence, precision and world-class experiences. The partnership is an exciting addition to NetJets' growing portfolio of premium lifestyle and sporting partnerships, offering Owners unique opportunities to access one of Europe's most iconic winter sporting events. Alongside premium hospitality and unforgettable behind-the-scenes experiences, the collaboration will help create extraordinary moments for Owners, both in the air and on the ground in Kitzbühel. “Kitzbühel is synonymous
Frontgrade Technologies Help Power Critical Computing and Electronics Aboard NASA’s Roman Space Telescope20.11.2026 19:40:00 EET | Press release
Frontgrade today announced that technologies from across its space electronics portfolio are supporting multiple mission-critical systems aboard NASA’s Nancy Grace Roman Space Telescope, which successfully launched on August 30, 2026. Roman is NASA’s flagship astrophysics observatory designed to investigate dark energy, discover exoplanets and explore the evolution of the universe. Its onboard electronics include radiation-hardened processors and microelectronics, providing critical processing, communications, power-management and control functions across the spacecraft. At the centre of Roman’s computing architecture are Frontgrade Gaisler’s GR740 and GR712RC processors. The GR740 radiation-hardened quad-core LEON4FT processor serves as the computing engine for the Wildcat Processor Card, used in the spacecraft’s primary and redundant Command and Data Handling systems as well as the Instrument Command and Data Handling systems for both the Wide Field Instrument and Coronagraph Instrum
Inside Moutai House Singapore: Beyond Baijiu, A Cultural Encounter20.11.2026 17:05:00 EET | Press release
On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120301288/en/ On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. As the world’s first Moutai brand experience space built under its new SI standards, this three-storey venue brings together cultural exhibitions, baijiu tasting, distinctive dining and creative cocktails. Using Moutai as a bridge, it creates new opportunities for Chinese baijiu culture to blend with and draw inspiration from Singapore’s diverse lifestyle and cultural scene. As early as 1954, Guizhou Moutai arrived in Singapore via the Singapore River, marking its first entry into Southeast Asia, right across from Fullerton Waterboat House. 72 years later, Moutai House has found its home along the same riverbank, transforming a historic arrival into a lasting presence and turning a con
ViTAA Medical and The Society for Vascular Surgery Announce Strategic Partnership20.11.2026 16:00:00 EET | Press release
ViTAA Medical Solutions Inc. (ViTAA) today announced a strategic partnership with The Society for Vascular Surgery (SVS) to advance evidence, education, and the responsible adoption of quantitative imaging and artificial intelligence in vascular care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120954362/en/ The partnership will support evidence building, best practices, educational resources for SVS members, physicians and trainees on AI validation, interpretation, and clinical limitations. The relationship has the potential to pave the way for additional AI tools and resources for SVS members through the Society in the future. The partnership creates a framework for the organizations to lead AI-enabled research opportunities involving imaging and clinical outcomes. Mitchel Benovoy, PhD, Chief Executive Officer at ViTAA Medical said: “The SVS deserves credit for its foresight in embracing advances in AI, digital healt
Epitech Group and Horus Pharma sign a global licensing agreement to develop adelmidrol in eye health20.11.2026 15:39:00 EET | Press release
Epitech Group S.p.A., an Italian biopharmaceutical firm specializing in neuro-inflammation, and Horus Pharma, a French laboratory specializing in ophthalmology, announce a global licensing agreement for adelmidrol, a molecule belonging to the ALIAmide family, developed by Epitech Group. This agreement grants Horus Pharma exclusive rights to develop and market adelmidrol for human ophthalmology and periocular dermatology applications. It aims to explore new approaches to address unmet medical needs in eye health. A combination of complementary scientific expertise Epitech Group has been studying ALIAmides and their role in physiological regulatory mechanisms for over 30 years, building on the research of Rita Levi-Montalcini, the 1986 Nobel Prize in Medicine laureate who first identified the ALIA mechanism. Horus Pharma, for its part, contributes over 20 years of ophthalmology expertise, strong R&D capabilities, and its international presence. Against the backdrop of an aging population
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
